Home Transmembrane Transporters Calcium Channel inhibitor Ethosuximide For research use only.

Ethosuximide

Synonyms: Zarontin

Ethosuximide(Zarontin) is a succinimide anticonvulsant, used mainly in absence seizures; A calcium channel blocker.

Ethosuximide Chemical Structure

Ethosuximide Chemical Structure

CAS No. 77-67-8

Purity & Quality Control

Ethosuximide Related Products

Signaling Pathway

Calcium Channel Signaling Pathways

Calcium Channel Signaling Pathway

Biological Activity

Description Ethosuximide(Zarontin) is a succinimide anticonvulsant, used mainly in absence seizures; A calcium channel blocker.
In vitro
In vitro

Ethosuximide(ETH) enhances hippocampal derived NSC proliferation and neurospheres formation in vitro. Low concentration of ETH induces proliferation of NSC, while higher concentrations of ETH are cytotoxic. Also, ETH activates the PI3K/Akt signal transduction pathway in adult hippocampal NSC in vitro. Blockade of the PI3K/Akt pathway inhibits ETH induced hippocampal NSC neuronal differentiation[3].
Cell Research Cell lines Mouse neuroblastoma cell line (N2A)
Concentrations 0.1, 0.56, 1 mg/ml
Incubation Time 5 h
Method

Mouse Neuro2A (N2A) neuroblastoma cells are cultured on 6-well plates and treated with retinoic acid to induce neuronal differentiation. After 24 h, N2A cells are treated with vehicle control (PBS) or increasing concentrations of ethosuximide for 5 h. Total RNA is then isolated, DNase-treated and reverse transcribed to cDNA. qRT-PCR is run above normalising to the reference genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin (ACTB).
In Vivo
In vivo

Anti-epileptic drug ethosuximide rescues the short lifespan and chemosensory defects exhibited by C. elegans null mutants of dnj-14, the worm orthologue of the DNAJC5 gene mutated in autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. It also ameliorates the locomotion impairment and short lifespan of worms expressing a human Tau mutant that causes frontotemporal dementia[1]. Ethosuximide extends lifespan by inhibiting the function of specific chemosensory neurons[2]. It increases neurogenesis, reduces neurodegeneration, and reverses cognitive impairments in rat model of AD like phenotypes[3].
Animal Research Animal Models Adult Wistar rats
Dosages 125 mg/kg
Administration i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02973542 Unknown status
Irritable Bowel Syndrome
University Hospital Clermont-Ferrand|SFETD (Socièté Française d''Etude et de Traitement de la Douleur)
 April 30 2018 Phase 2
NCT02100046 Completed
Neuropathic Traumatic Pain|Pain NRS ≥ 4|Peripheral Neuropathic Pain|Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4
University Hospital Clermont-Ferrand|Fondation Apicil
 March 2014 Phase 2

Chemical Information & Solubility

Molecular Weight 141.17 Formula

C7H11NO2
CAS No. 77-67-8 SDF Download Ethosuximide SDF
Smiles CCC1(CC(=O)NC1=O)C
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 28 mg/mL ( (198.34 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 28 mg/mL

Ethanol : 28 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Ethosuximide | Ethosuximide ic50 | Ethosuximide price | Ethosuximide cost | Ethosuximide solubility dmso | Ethosuximide purchase | Ethosuximide manufacturer | Ethosuximide research buy | Ethosuximide order | Ethosuximide mouse | Ethosuximide chemical structure | Ethosuximide mw | Ethosuximide molecular weight | Ethosuximide datasheet | Ethosuximide supplier | Ethosuximide in vitro | Ethosuximide cell line | Ethosuximide concentration | Ethosuximide nmr